Experimental combo targets Hard-to-Treat pancreatic cancer
NCT ID NCT06015659
First seen Feb 10, 2026 · Last updated Jun 22, 2026 · Updated 19 times
Summary
This phase 2 trial tests a new drug called ZN-c3 combined with the chemotherapy gemcitabine in 12 people with advanced pancreatic cancer that has worsened after platinum-based treatment. The goal is to see if the combination is safe and can slow cancer growth. Participants take ZN-c3 pills and receive gemcitabine infusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZN-c3 (a WEE1 inhibitor) and gemcitabine (chemotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for advanced pancreatic cancer patients who have stopped responding to standard chemotherapy.
What could go wrong
This is a small, single-arm phase 2 trial with only 12 participants, so results may not apply broadly. The combination may cause significant side effects and may not improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.